ACSS3 represses prostate cancer progression through downregulating lipid droplet-associated protein PLIN3

Current endocrine therapy for prostate cancer (PCa) mainly inhibits androgen/androgen receptor (AR) signaling. However, due to increased intratumoural androgen synthesis and AR variation, PCa progresses to castration-resistant prostate cancer (CRPC), which ultimately becomes resistant to endocrine t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Theranostics
Autors principals: Zhou, Lijie, Song, Zhengshuai, Hu, Junyi, Liu, Lilong, Hou, Yaxin, Zhang, Xiaoping, Yang, Xiong, Chen, Ke
Format: Artigo
Idioma:Inglês
Publicat: Ivyspring International Publisher 2021
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7738848/
https://ncbi.nlm.nih.gov/pubmed/33391508
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.49384
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars